Dali Pharmaceuticalco.,Ltd

As of September 30, 2024, Dali Pharmaceuticalco.,Ltd has 219.70M shares outstanding.

These figures are as of September 30, 2024. The price-to-sales ratio is 10.89, and the price-to-book ratio stands at 3.18.

These figures are as of September 30, 2024. The EV/Sales ratio of 7.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Dali Pharmaceuticalco.,Ltd trades at an EV/FCF ratio of 89.45, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2024, Dali Pharmaceuticalco.,Ltd maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.49, indicating elevated leverage, while an interest coverage ratio of -26.08 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2024, Dali Pharmaceuticalco.,Ltd posted a negative return on equity (ROE) of -10.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.33, reflecting losses generated across the asset base. Inventory turnover of 1.09 indicates how many times Dali Pharmaceuticalco.,Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on March 4, 2025, Dali Pharmaceuticalco.,Ltd's stock has declined approximately 85.06% over the past 52 weeks. The 50-day moving average sits at 1.83, while the 200-day moving average is 2.85.

Over the twelve months ended September 30, 2024, Dali Pharmaceuticalco.,Ltd posted a gross margin of 7.58, reflecting its pricing power and cost economics. The operating margin of -45.75 and net profit margin of -39.55 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. The dividend payout ratio of -4.28 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.63, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dali Pharmaceuticalco.,Ltd shareholders.

Dali Pharmaceuticalco.,Ltd's most recent stock split took place on June 8, 2020 with a 10:13 split ratio.

As of September 30, 2024, Dali Pharmaceuticalco.,Ltd has an Altman Z-Score of 5.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.